Sign Up
Stories
EMA Backs Ocugen's Gene Therapy
Share
4D Molecular Therapeutics Raises $300 Mi...
4DMT Presents Positive Interim Data
Advancements in Cancer Treatment and Mar...
Biopharma Innovator GeNeuro Discloses Pr...
Genomic Tech's Investment Potential
Innovative GI Drug Data Revealed
Overview
API
Ocugen, Inc. receives positive support from the EMA for OCU400 gene therapy to treat retinitis pigmentosa, aligning with FDA clearance for Phase 3 trial. The therapy aims for approval in 2026.
Ask a question
How does the EMA's positive advice impact the global perception of Ocugen's gene therapy?
How might the success of OCU400 influence the development and accessibility of gene therapies for other genetic disorders in the future?
What challenges might Ocugen face in the approval process for OCU400 despite the favorable responses from regulatory bodies?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Jan 2024
Feb 2024
Mar 2024
Coverage